

Roberto Sorio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2067993/publications.pdf>

Version: 2024-02-01

127
papers

5,667
citations

147726

31
h-index

82499

72
g-index

130
all docs

130
docs citations

130
times ranked

6086
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>CDKN1B</i> mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer. <i>Journal of Pathology</i> , 2021, 253, 234-245.	2.1	12
2	Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives. <i>Cancers</i> , 2021, 13, 3035.	1.7	12
3	Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. <i>International Journal of Cancer</i> , 2020, 146, 439-448.	2.3	40
4	A TGF- β 2 associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 233-242.	0.6	5
5	TIMP-1 Is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells. <i>Cells</i> , 2020, 9, 6.	1.8	20
6	Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC). <i>Cells</i> , 2019, 8, 1186.	1.8	10
7	New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach. <i>Cells</i> , 2019, 8, 584.	1.8	25
8	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 862-876.	5.1	68
9	Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials. <i>Gynecologic Oncology</i> , 2019, 154, 83-88.	0.6	9
10	Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. <i>Annals of Oncology</i> , 2018, 29, 1189-1194.	0.6	8
11	Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS). <i>International Journal of Molecular Sciences</i> , 2018, 19, 1510.	1.8	10
12	A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of paclitaxel and 6 β -hydroxy-paclitaxel in human plasma: Development, validation and application in a clinical pharmacokinetic study. <i>PLoS ONE</i> , 2018, 13, e0193500.	1.1	14
13	Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project. <i>Supportive Care in Cancer</i> , 2017, 25, 1743-1748.	1.0	1
14	Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells. <i>Scientific Reports</i> , 2017, 7, 7104.	1.6	28
15	CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation. <i>EMBO Molecular Medicine</i> , 2017, 9, 1415-1433.	3.3	61
16	Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. <i>Gynecologic Oncology</i> , 2017, 144, 65-71.	0.6	21
17	Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3347-3353.	0.8	66
18	Development and validation of a microRNA-based signature (MIROvar) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. <i>Lancet Oncology</i> , The, 2016, 17, 1137-1146.	5.1	97

#	ARTICLE	IF	CITATIONS
19	Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial. <i>Annals of Oncology</i> , 2016, 27, 487-493.	0.6	51
20	The MITO8 phase III international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum-based chemotherapy: A collaboration of MITO, MANGO, AGO, BGOG, ENGOT, and GCIG.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5505-5505.	0.8	13
21	Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. <i>Oncotarget</i> , 2016, 7, 72654-72661.	0.8	15
22	Idarubicin. <i>Reactions Weekly</i> , 2015, 1538, 128-128.	0.0	0
23	Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5502-5502.	0.8	34
24	Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0140351.	1.1	17
25	Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 396-405.	5.1	327
26	Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study. <i>Journal of Ovarian Research</i> , 2014, 7, 72.	1.3	12
27	Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1309-1316.	0.8	154
28	Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1302-1308.	0.8	1,240
29	Phase II prospective study on trabectedin (T) in BRCA-mutated and BRCAness phenotype advanced ovarian cancer (AOC) patients (pts): The MITO 15 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5530-5530.	0.8	2
30	A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). <i>Gynecologic Oncology</i> , 2013, 130, 31-37.	0.6	20
31	A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9845-9850.	3.3	176
32	Paraneoplastic cerebellar degeneration associated with ovarian cancer. <i>Oncology Letters</i> , 2013, 5, 681-683.	0.8	10
33	Revisiting the Clinical Value of 18F-FDG PET/CT in Detection of Recurrent Epithelial Ovarian Carcinomas. <i>Clinical Nuclear Medicine</i> , 2012, 37, e184-e188.	0.7	50
34	Lapatinib-Based Therapy in Heavily Pretreated HER2-Positive Metastatic Breast Cancer: A Single Institution Experience. <i>Tumori</i> , 2012, 98, 33-38.	0.6	4
35	Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?. <i>Archives of Gynecology and Obstetrics</i> , 2012, 285, 499-503.	0.8	0
36	Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience. <i>Tumori</i> , 2012, 98, 33-8.	0.6	4

#	ARTICLE	IF	CITATIONS
37	Multimodality approach in extra cervical locally advanced cervical cancer: Chemoradiation, surgery and intra-operative radiation therapy. A phase II trial. <i>European Journal of Surgical Oncology</i> , 2011, 37, 442-447.	0.5	22
38	Surgical and Medical Treatment of Clear Cell Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1063-1070.	1.2	43
39	A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1347-1353.	1.1	8
40	Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3628-3635.	0.8	182
41	Genetic profiling™ and ovarian cancer therapy (Review). <i>Molecular Medicine Reports</i> , 2011, 4, 771-7.	1.1	25
42	Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. <i>British Journal of Cancer</i> , 2011, 105, 360-365.	2.9	28
43	Abstract 332: B-Raf mutations are associated with a worse outcome in ovarian cancer. , 2011, , .		0
44	Multicenter Phase 2 Study of Combined Gemcitabine and Epirubicin as Second-Line Treatment for Patients With Advanced Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 953-957.	1.2	5
45	Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): Final analysis of the MITO-2 randomized multicenter trial. <i>Journal of Clinical Oncology</i> , 2010, 28, LBA5033-LBA5033.	0.8	7
46	Incidence of Palmar-Plantar Erythrodysesthesia in Pretreated and Unpretreated Patients Receiving Pegylated Liposomal Doxorubicin. <i>Tumori</i> , 2009, 95, 687-690.	0.6	3
47	Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial. <i>Oncology</i> , 2009, 76, 49-54.	0.9	30
48	Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: Results from the SOCRATES retrospective study. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 233-241.	2.0	32
49	A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1021-1027.	1.1	8
50	Uterine cervical carcinoma: Role of matrix metalloproteinases (Review). <i>International Journal of Oncology</i> , 2009, 34, 897-903.	1.4	103
51	Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): Activity and safety results of the MITO-2 randomized multicenter trial. <i>Journal of Clinical Oncology</i> , 2009, 27, LBA5508-LBA5508.	0.8	5
52	Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. <i>BMC Cancer</i> , 2008, 8, 252.	1.1	44
53	Phase II study on pemetrexed in advanced and/or recurrent cervical cancer patients: a MITO study. <i>Journal of Clinical Oncology</i> , 2008, 26, 5515-5515.	0.8	1
54	Nemorubicin hydrochloride (nemorubicin) in combination with cisplatin (cDDP): Phase I in patients (pts) with hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2008, 26, 2572-2572.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a randomized study. <i>Journal of Clinical Oncology</i> , 2008, 26, 594-594.	0.8	0
56	Gemcitabine (G) and epirubicin (E) combination, in platinum-resistant or refractory advanced ovarian cancer (PROC) patients: Results of a multicentric phase II trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 5566-5566.	0.8	1
57	Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group. <i>Clinical Cancer Research</i> , 2007, 13, 6410-6418.	3.2	101
58	Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2007, 46, 1051-1068.	1.6	42
59	A centralized Pharmacy Unit for cytotoxic drugs in accordance with Italian legislation. <i>Journal of Evaluation in Clinical Practice</i> , 2007, 13, 265-271.	0.9	11
60	Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: A study by the EORTC-PAMM-NDDG. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 505-505.	1.1	3
61	Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 986-992.	1.2	5
62	A study from the EORTC new drug development group: Open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer. <i>European Journal of Cancer</i> , 2006, 42, 200-204.	1.3	20
63	Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. <i>BMC Cancer</i> , 2006, 6, 202.	1.1	21
64	Oral Etoposide in Elderly Patients with Advanced Non Small Cell Lung Cancer: A Clinical and Pharmacological Study. <i>Journal of Chemotherapy</i> , 2006, 18, 188-191.	0.7	5
65	Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring. <i>Annals of Oncology</i> , 2006, 17, 807-812.	0.6	20
66	Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer. <i>Oncology</i> , 2006, 71, 320-326.	0.9	30
67	Gemcitabine and anthracyclines in platinum-resistant ovarian cancer. <i>Annals of Oncology</i> , 2006, 17, v195-v198.	0.6	6
68	A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer. <i>Investigational New Drugs</i> , 2005, 23, 85-89.	1.2	15
69	A Phase II Study of Liposomal Doxorubicin in Recurrent Epithelial Ovarian Carcinoma. <i>Tumori</i> , 2004, 90, 556-561.	0.6	12
70	Long-Term, weekly One-Hour Infusion of Paclitaxel in Patients with Metastatic Breast Cancer: A Phase II Monoinstitutional Study. <i>Tumori</i> , 2004, 90, 285-288.	0.6	33
71	Vinorelbine-induced acute reversible peripheral neuropathy in a patient with ovarian carcinoma pretreated with carboplatin and paclitaxel. <i>Acta Oncologica</i> , 2004, 43, 209-211.	0.8	8
72	Pharmacokinetic Comparison of 120-Hour Infusion Versus Hyperfractionated Oral Administration of Idarubicin. <i>Journal of Chemotherapy</i> , 2004, 16, 193-200.	0.7	2

#	ARTICLE	IF	CITATIONS
73	Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer. <i>Investigational New Drugs</i> , 2003, 21, 347-352.	1.2	22
74	Treatment of older breast cancer patients with high recurrence risk. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 46, 241-246.	2.0	8
75	Ifosfamide in Advanced/Disseminated Breast Cancer. <i>Oncology</i> , 2003, 65, 55-58.	0.9	11
76	Cisplatin may be a Valid Alternative Approach in Ovarian Carcinoma with Carboplatin Hypersensitivity. Report of Three Cases. <i>Tumori</i> , 2003, 89, 311-313.	0.6	12
77	Long-Term Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Continuous Intravenous Infusion of Recombinant Interleukin-2: The Experience of a Single Institution. <i>Tumori</i> , 2003, 89, 400-404.	0.6	6
78	Carboplatin and Topotecan Combination and Myelosuppression. <i>Journal of Clinical Oncology</i> , 2002, 20, 3558-3558.	0.8	5
79	Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. <i>Annals of Oncology</i> , 2002, 13, 777-780.	0.6	31
80	Carboplatin in Elderly Patients. <i>Tumori</i> , 2002, 88, S35-S36.	0.6	0
81	Occult Small Cell Lung Cancer Associated with Paraneoplastic Neurologic Syndrome: Case Report. <i>Tumori</i> , 2001, 87, 447-450.	0.6	0
82	Phase II Study of Sequential Administration of Docetaxel Followed by Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 3367-3375.	0.8	18
83	Population pharmacokinetics and pharmacodynamics of oral etoposide. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 511-519.	1.1	48
84	Resistance to methotrexate in SKOV-3 cell lines after chronic exposure to carbamazepine is associated with a decreased expression of folate receptor. , 2000, 85, 683-690.		11
85	Local chemotherapy for neoplastic pericardial effusion. <i>American Journal of Cardiology</i> , 2000, 86, 1292.	0.7	13
86	Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 167-171.	1.1	37
87	Interactions of Antineoplastic Chemotherapy with Zidovudine Pharmacokinetics in Patients with HIV-Related Neoplasms. <i>Chemotherapy</i> , 1999, 45, 418-428.	0.8	8
88	Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 1999, 91, 66-72.	3.0	901
89	Anthracycline dose and liver dysfunction. <i>British Journal of Cancer</i> , 1999, 79, 1943-1943.	2.9	0
90	Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 287-294.	1.1	44

#	ARTICLE	IF	CITATIONS
91	Pharmacology study of chronic oral idarubicin for breast cancer. <i>European Journal of Cancer</i> , 1999, 35, S291-S292.	1.3	0
92	Long term follow up of 50 patients with metastatic renal cell carcinoma treated with high dose i.v. interleukin. 2. <i>European Journal of Cancer</i> , 1999, 35, S358.	1.3	0
93	Effect of cyclosporin A on protein binding of teniposide in cancer patients. <i>Anti-Cancer Drugs</i> , 1999, 10, 511-518.	0.7	9
94	Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma. <i>Anti-Cancer Drugs</i> , 1999, 10, 815-820.	0.7	5
95	Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. , 1998, 79, 121-126.		138
96	Dose finding and pharmacokinetic (PK) study of daily oral Idarubicin (IDA) in metastatic breast cancer (MBC). <i>European Journal of Cancer</i> , 1997, 33, S251.	1.3	0
97	Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. <i>European Journal of Cancer</i> , 1997, 33, 301-303.	1.3	75
98	Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study.. <i>Journal of Clinical Oncology</i> , 1997, 15, 1418-1426.	0.8	46
99	Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide. <i>British Journal of Cancer</i> , 1997, 75, 715-721.	2.9	13
100	Reversal activity of cyclosporin A and its metabolites M1, M17 and M21 in multidrug-resistant cells. , 1997, 71, 900-906.		10
101	Liver Function Assessment by MEGX.. <i>Annals of the New York Academy of Sciences</i> , 1996, 784, 486-490.	1.8	4
102	EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. <i>European Journal of Cancer</i> , 1996, 32, 2019-2022.	1.3	60
103	Sensitive high-performance liquid chromatographic method with fluorescence detection for measurement of vinorelbine plasma concentrations. <i>Biomedical Applications</i> , 1996, 675, 183-187.	1.7	20
104	Pharmacokinetics of vinorelbine in patients with liver metastases. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 32-40.	2.3	72
105	Determination of unbound etoposide concentration in ultrafiltered plasma by high-performance liquid chromatography with fluorimetric detection. <i>Biomedical Applications</i> , 1996, 686, 35-41.	1.7	29
106	Hepatitis C virus and non-Hodgkin's lymphomas. <i>British Journal of Haematology</i> , 1996, 94, 544-550.	1.2	171
107	Effect of cyclosporine on teniposide pharmacokinetics and pharmacodynamics in patients with renal cell cancer. <i>Anti-Cancer Drugs</i> , 1995, 6, 479-482.	0.7	0
108	Entry and evaluation of elderly patients in european organization for research and treatment of cancer (EORTC) new-drug development studies. <i>Cancer</i> , 1995, 76, 333-338.	2.0	96

#	ARTICLE	IF	CITATIONS
109	Should elderly cancer patients be entered in dose-escalation studies?. <i>Annals of Oncology</i> , 1994, 5, 964-965.	0.6	10
110	Hodgkin's disease in patients with HIV infection and in the general population: Comparison of clinicopathological features and survival. <i>Annals of Oncology</i> , 1994, 5, S37-S40.	0.6	21
111	Acute morphine intoxication during high-dose recombinant interleukin-2 treatment for metastatic renal cell cancer. <i>European Journal of Cancer</i> , 1994, 30, 1905-1907.	1.3	12
112	The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2. <i>European Journal of Cancer</i> , 1994, 30, 329-333.	1.3	31
113	Epirubicin and ifosfamide in advanced soft tissue sarcomas. <i>Annals of Oncology</i> , 1993, 4, 669-672.	0.6	26
114	Feasibility and efficacy of arginine 2-mercaptoethanesulfonate (ARGIMESNA) in the prevention of hemorrhagic cystitis from ifosfamide (IFO). <i>Annals of Oncology</i> , 1992, 3, S115-S118.	0.6	2
115	Evaluation of Two Consecutive Regimens in Advanced Gastric Cancer. <i>Cancer Investigation</i> , 1991, 9, 257-262.	0.6	6
116	A Phase II Study of Oral Idarubicin (4-Demethoxidaunorubicin) in Previously Untreated Elderly Patients with Non-Hodgkin's Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1991, 14, 243-245.	0.6	25
117	Phase II studies of 4-iodo-4'-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers. <i>Annals of Oncology</i> , 1991, 2, 727-731.	0.6	10
118	Natural killer (NK) and lymphokine activated killer (LAK) cell activity in patients (PTS) treated with flavone acetic acid (FAA). <i>Annals of Oncology</i> , 1991, 2, 145-150.	0.6	6
119	Phase II Study of Teniposide (VM26) in Cutaneous T-Cell Lymphomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1990, 13, 14-16.	0.6	3
120	Flavone acetic acid distribution in human malignant tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 67-70.	1.1	6
121	Combination Chemotherapy Specifically Devised for Elderly Patients with Unfavorable Non-Hodgkin's Lymphoma. <i>Cancer Investigation</i> , 1990, 8, 577-582.	0.6	24
122	Human immunodeficiency virus (HIV) infection among prisoners in Northeastern Italy. <i>Infection</i> , 1988, 16, 251-251.	2.3	1
123	Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion. <i>Cancer Chemotherapy and Pharmacology</i> , 1987, 20, 239-242.	1.1	21
124	INCREASED PREVALENCE OF HTLV-III ANTIBODY AMONG DRUG ADDICTS FROM ITALIAN PROVINCE WITH US MILITARY BASE. <i>Lancet, The</i> , 1986, 327, 804.	6.3	8
125	Combination chemotherapy with fluorouracil, adriamycin, cis-Platinum and VM-26 in advanced transitional cell carcinoma of the urinary tract. <i>European Journal of Cancer & Clinical Oncology</i> , 1986, 22, 1457-1460.	0.9	2
126	HTLV-III INFECTION AMONG 315 INTRAVENOUS DRUG ABUSERS: SEROEPIDEMIOLOGICAL, CLINICAL, AND PATHOLOGICAL FINDINGS. <i>AIDS Research</i> , 1986, 2, 325-334.	0.5	6

#	ARTICLE	IF	CITATIONS
127	HTLV-III Antibodies in Drug-Addicted Prostitutes Used by US Soldiers in Italy. JAMA - Journal of the American Medical Association, 1986, 256, 711.	3.8	4